menu
    • menu
    [{"orgOrder":0,"company":"Terran Biosciences","sponsor":"Terran Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Terran Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Terran Biosciences \/ Terran Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Terran Biosciences \/ Terran Biosciences"},{"orgOrder":0,"company":"Terran Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Terran Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Terran Biosciences \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Terran Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Terran Biosciences","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Idazoxan","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Terran Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Terran Biosciences \/ Terran Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Terran Biosciences \/ Terran Biosciences"},{"orgOrder":0,"company":"Terran Biosciences","sponsor":"Concert Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Terran Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Terran Biosciences \/ Terran Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"Terran Biosciences \/ Terran Biosciences"},{"orgOrder":0,"company":"Terran Biosciences","sponsor":"old Sano","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"Tolebrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Neurology","graph2":"Phase III","graph3":"Terran Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Terran Biosciences \/ old Sano","highestDevelopmentStatusID":"10","companyTruncated":"Terran Biosciences \/ old Sano"},{"orgOrder":0,"company":"Terran Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TR-01-XRR","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Terran Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Terran Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Terran Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Terran Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Trospium Prodrug","moa":"||Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Terran Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Terran Biosciences \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Terran Biosciences \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Terran Biosciences

    Menu

    Terran Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Terran Biosciences

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Terran Biosciences

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Xanomeline Prodrug,Trospium Prodrug

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Terran Announces Develop of TerXT, Xanomeline &Trospium Prodrugs for Schizophrenia

                            Details : TerXT, is a small molecule combination of novel prodrugs of xanomeline and trospium designed to enable fixed-dose combinations for once-daily oral administration for the treatment for schizophrenia.

                            Product Name : TerXT

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 20, 2024

                            Lead Product(s) : Xanomeline Prodrug,Trospium Prodrug

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Terran Biosciences

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Terran Biosciences

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Idazoxan

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Recipient : Pierre Fabre

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Terran Biosciences Announces Exclusive Licensing Deal with Pierre Fabre for Idazoxan; Terran Completes Key Dev...

                            Details : Under the agreement, Terran obtains exclusive global development and commercialization rights for idazoxan hydrochloride, a selective alpha 2 receptor antagonist and a late-stage clinical therapeutic for the treatment of schizophrenia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            June 02, 2023

                            Lead Product(s) : Idazoxan

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Recipient : Pierre Fabre

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Terran Biosciences

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Terran Biosciences

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TR-01-XRR

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Idazoxan in Healthy Participants

                            Details : TR-01-XRR is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            February 14, 2023

                            Lead Product(s) : TR-01-XRR

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Terran Biosciences

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Terran Biosciences

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dimethyltryptamine

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Terran Biosciences Announces Publication Of PCT Patent Applications Covering Orally Active Forms Of DMT and 5-...

                            Details : N,N-dimethyltryptamine is a psychedelic tryptamine, non-selective agonist for 5HT2a receptor being developed as a therapy for patients with neurological & mental illness.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            February 03, 2023

                            Lead Product(s) : Dimethyltryptamine

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Terran Biosciences

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Terran Biosciences

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tolebrutinib

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : old Sano

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Terran Biosciences Announces Licensing Deal with Sanofi for Two Late-Stage CNS Pipeline Assets

                            Details : Terran plans to quickly advance the development of the lead SAR442168 and other assets for neurological and psychiatric indications, which include several novel applications where there is a large unmet medical need.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            April 21, 2022

                            Lead Product(s) : Tolebrutinib

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : old Sano

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Terran Biosciences

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Terran Biosciences

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dimethyltryptamine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Preclinical

                            Recipient : Blumentech S.L.

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Terran Biosciences and Blumentech S.L. Announce the Acquisition of a Patent Portfolio Covering the Groundbreak...

                            Details : Blumentech's patents further complement Terran's rapidly growing IP portfolio of over 150 patent applications in the psychedelic space, which includes patents on Terran's orally-active DMT compound, a product of Terran's robust medicinal chemistry drug d...

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            April 13, 2022

                            Lead Product(s) : Dimethyltryptamine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Preclinical

                            Recipient : Blumentech S.L.

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Terran Biosciences

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Terran Biosciences

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Deuruxolitinib phosphate

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Recipient : Concert Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Terran Biosciences Announces Acquisition of A Portfolio of Novel CNS Therapeutics from Concert Pharmaceuticals

                            Details : Terran plans to quickly accelerate the development of these compounds as important complements to a growing pipeline of both early-stage and late-stage therapeutics and technologies in the CNS space.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            March 11, 2022

                            Lead Product(s) : Deuruxolitinib phosphate

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Recipient : Concert Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth